Treatment delivered inside the eye for retinoblastoma
Treatments studied
Part of Cancer, Eyes & vision clinical trials.
This Phase 2 study tests a way to deliver cancer treatment directly inside the eye to treat retinoblastoma. It may help shrink the tumor while limiting treatment to the eye when possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be under 18 years old when you join the study
- You must have newly diagnosed retinoblastoma that is only in the eye (not spread elsewhere)
- The tumor pattern must match specific “Group D/E” eye categories and may involve “vitreous seeding” in one or both eyes
- No cancer treatment before starting this study, except laser and/or freezing (cryotherapy) for eye(s)
- Your child must have adequate blood counts and organ health based on recent lab tests (blood counts, kidney function, liver/bilirubin tests)
- You must not have an active invasive infection, and any required pregnancy/contraception rules must be followed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at long-term health outcomes—how patients are doing physically and in daily life—after treatment for retinoblastoma. It may help doctors understand what support or follow-up care could be most helpful after treatment.
This trial studies whether newer “save-the-eye” treatment plans can control retinoblastoma (eye cancer) while keeping vision as good as possible. It compares different conservative treatment strategies depending on how the tumor looks and where it is.
This trial tests a high dose of a chemotherapy drug called topotecan given directly into the eye (intravitreal injection) for children with retinoblastoma that has come back or not responded to treatment and has seeds floating in the vitreous. The goal is to save the eye when removal is the only other option.
This trial looks at care recommendations for children with retinoblastoma (a childhood eye cancer). It may help standardize the best treatment approach for different patterns of tumor spread.
This Phase 3 study tests whether giving chemotherapy after the eye has been removed can lower the chance of retinoblastoma coming back for children with high-risk disease. You may be screened if your child had one eye affected and meet the staging and treatment history requirements.
This trial tests a new way to deliver the chemotherapy drug topotecan directly to the eye (via a small patch placed on the eye surface) for children with retinoblastoma that either needs eye removal or has come back after standard treatment. It aims to see if this approach can help save the eye and vision.
Hear when a new Bilateral Retinoblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.